Pneumococcal Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Pneumococcal Vaccines Market is Segmented by Vaccine Type (Conjugate vaccine, Polysaccharide vaccine), Product Type, Distribution Channel, and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pneumococcal vaccines market studied was projected to grow with a CAGR of nearly 7.5% over the forecast period. The major factor attributing to the growth of the market increasing the prevalence of pneumococcal contaminations. 

According to National Center for Immunization and Respiratory Diseases, each year in the United States, more than 250,000 people are hospitalized due to pneumonia and about 50,000 people die from the disease each year in the United States. Furthermore, the growing awareness programs initiated by the government are also boosting the market growth. Rising production of novel vaccines is also another major factor for market growth. 

However, the high cost involved in the production of vaccines, and the long duration for the process of production are the major drawbacks for market growth.

Scope of the Report

As per the scope of the report, Pneumonia is a type of acute respiratory illness that affects the lungs, in which the alveoli are filled with pus and fluid, which makes breathing painful and limits oxygen intake. This report is segmented by Vaccine Type, Product Type, Distribution Channel, and Geography.

By Vaccine Type
Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine
By Product Type
Prevnar 13
By Distribution Channel
Distribution partner companies
Non-governmental Organizations
Government Authorities
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Pneumococcal conjugate vaccine segment expected to dominate the market throughout the forecast period

A conjugate vaccine is a substance that is comprised of a polysaccharide antigen fused to a carrier molecule. This improves the stability and efficacy of the vaccine. The Pneumococcal conjugate vaccine segment is a major contributor to the global pneumonia vaccine market, this is credited to the wide age group that is covered by this type of vaccine. These vaccines can vaccinate infants and children from 6 weeks to 5 years of age to prevent pneumonia and acute otitis media.

Furthermore, the conjugate vaccine stimulates immunological memory and reduces asymptomatic delivery of the bacteria, resulting in marked group immunity. Hence this segment has a higher market share.


North America Dominates the Market and Asia Pacific is Expected to grow at a higher CAGR in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. Factors such as the presence of key players and established healthcare infrastructure are the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. The Asia Pacific is the fastest-growing region due to the high prevalence of pneumococcal infection. The major countries of this region have the highest-burden in the world and hence there is more need for vaccination to prevent the disease.

Venipuncture Needles and Syringes Market

Competitive Landscape

The pneumococcal vaccine market is highly consolidated and consists of a few players. Some of the companies which are currently dominating the market are GlaxoSmithKline plc, Pfizer Inc., CSL Ltd., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur Inc.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing government awareness programs regarding pneumonia immunization program

      2. 4.2.2 Rising prevalence of pneumococcal contaminations

      3. 4.2.3 Introduction of novel pneumococcal vaccines

    3. 4.3 Market Restraints

      1. 4.3.1 Long duration for the production

      2. 4.3.2 High cost of production

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Vaccine Type

      1. 5.1.1 Pneumococcal conjugate vaccine

      2. 5.1.2 Pneumococcal polysaccharide vaccine

    2. 5.2 By Product Type

      1. 5.2.1 Prevnar 13

      2. 5.2.2 Synflorix

      3. 5.2.3 Pneumovax23

    3. 5.3 By Distribution Channel

      1. 5.3.1 Distribution partner companies

      2. 5.3.2 Non-governmental Organizations

      3. 5.3.3 Government Authorities

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline plc

      2. 6.1.2 Pfizer Inc.

      3. 6.1.3 Merck & Co., Inc

      4. 6.1.4 Serum Institute of India Pvt. Ltd.

      5. 6.1.5 CSL Ltd.

      6. 6.1.6 Sanofi Pasteur Inc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pneumococcal Vaccines Market market is studied from 2018 - 2026.

The Pneumococcal Vaccines Market is growing at a CAGR of 7.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc, CSL Ltd., Serum Institute of India Pvt. Ltd. are the major companies operating in Pneumococcal Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!